FFO
KRYS icon

Fortitude Family Office’s Krystal Biotech KRYS Stock Holding History

Fortitude Family Office’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.32K Hold
13
– – ﹤0.01% 1642
2026
Q2 		$4.83K Buy
13
+2
+18% +$598 ﹤0.01% 1088
2026
Q1 		$2.84K Buy
11
+4
+57% +$1.06K ﹤0.01% 1143
2025
Q4 		$1.73K Buy
7
+3
+75% +$631 ﹤0.01% 1237
2025
Q3 		$706 Hold
4
– – ﹤0.01% 1672
2025
Q2 		$550 Buy
+4
New +$588 ﹤0.01% 1751

Other funds holding KRYS

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
TNAM
Terra Nova Asset Management New York $155M AUM 33.52% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office's KRYS Position: Q3 2026 in Review

Fortitude Family Office held its Krystal Biotech (KRYS) position steady in Q3 2026 at 13 shares worth $4.32K. The position accounts for ﹤0.01% of the portfolio, ranked #1642.

Fortitude Family Office first reported a position in KRYS in Q2 2025 and has held it in 6 quarters since. The position peaked at $4.83K in Q2 2026. 29 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Fortitude Family Office held 13 shares of Krystal Biotech worth $4.32K as of Q3 2026.
  • Fortitude Family Office left its Krystal Biotech share count unchanged in Q3 2026.
  • Krystal Biotech made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1642 holding.
  • Fortitude Family Office first reported a position in Krystal Biotech in Q2 2025 and has held it in 6 quarters since.
  • Fortitude Family Office's Krystal Biotech position peaked at $4.83K in Q2 2026.
  • 29 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.